The Truth About Premature Ejaculation

A UK company has launched a new spray aimed at delaying ejaculation. The spary contains two local anesthetics: lidocaine and prilocaine, drugs that dampen sensation. This approach to treating premature ejaculation is nothing new since creams have been around for a long time. The difference here is the onset of it’s effect. While creams take up to 30 minutes to take effect and may induce numbness to the vagina, the spray can be applied up to five minutes before penetration and is readily absorbed.

Initial analyses show that PSD502 produced a highly clinically and statistically significant increase from baseline in all three co-primary study endpoints. The intravaginal ejaculation latency time (IELT) geometric mean for PSD502 was 4 minutes compared to 1 (one) minute in placebo (p<0.0001). There was a 7 point difference between PSD502 and placebo in the IPE domain for Ejaculatory Control (p<0.0001) and a 6 point difference between PSD502 and placebo in the IPE domain for Sexual Satisfaction (p<0.0001), where a 2 point difference in a 16 point range is considered clinically significant.

There were no serious adverse events and only 2.6% of patients reported treatment-related adverse events in the PSD502 group compared with 1% in the placebo. PSD502 was well tolerated and there were no systemic adverse events.